: Gliomas are aggressive tumors with various molecular and clinical characteristics and exhibit strongly resistance to radio-chemotherapy. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein, which was reported in many cancers, modulating cancer-associated immune responses, while the role of PD-L2 in gliomas remained unclear. Herein, we aimed to investigate the biological behaviors and clinical prognostic values of PD-L2 in gliomas. : Totally, we enrolled RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) as training cohort and RNA expression data of 1032 samples from The Cancer Genome Atlas (TCGA) dataset as validation cohort in this research. Then, the clinical and molecular characteristics, and the prognostic value of PD-L2 were analyzed. : We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma. Receiver Operating Characteristic (ROC) analysis revealed that PD-L2 was a potential indicator of mesenchymal subtype. PD-L2 exhibited tight relationship with immune response and immune-modulating process in glioma. Moreover, PD-L2 expression level could predict unfavorable prognoses of patients independent of age, grade, IDH status and 1p/19q status. : Our study revealed that PD-L2 was closely related with inflammation and immune response. Patients with lower PD-L2 expression level tended to experience improved survival. Targeting PD-L2 may become a valuable approach for the treatment of gliomas in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343813 | PMC |
| http://dx.doi.org/10.1080/2162402X.2018.1541535 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1.
Front Immunol
December 2024
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Introduction: Immunotherapy, especially immune checkpoint blockade (ICB), holds promise as a therapeutic strategy in colorectal cancer (CRC) by harnessing the patient's immune system to target malignant cells. Particularly, the PD-1/PD-L1 axis is widely recognized for its critical role in tumor microenvironment immunosuppression. Antibodies targeting PD-1 or PD-L1 have shown sustained efficacy against various cancers, including CRC.
View Article and Find Full Text PDFEffect of decitabine on PD-L2 methylation in whole blood of iodine-induced autoimmune thyroiditis rats.
Ecotoxicol Environ Saf
December 2024
Department of Preventive Medicine, Qiqihar Medical University, Qiqihar, Heilongjiang, China. Electronic address:
Article Synopsis
- Excessive iodine intake can lead to autoimmune thyroiditis (AIT), with methylation changes in the PD-L2 gene potentially playing a crucial role in this condition.
- Researchers used Decitabine, a DNA methyltransferase inhibitor, in an experimental model to explore the effects on AIT, involving various biochemical and molecular techniques to assess thyroid function and immune responses.
- Results indicated that iodine-induced AIT was associated with decreased PD-L2 methylation and increased inflammatory markers, while treatment with Decitabine improved thyroid function trends and altered PD-L2 expression, though more safety evaluations are needed for this potential treatment.
Holliday junction recognition protein (HJURP) could reflect the clinical outcomes of lung adenocarcinoma patients, and impact the choice of precision therapy.
Front Genet
November 2024
Department of Respiratory, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer (NSCLC), characterized by poor prognosis and a high mortality rate. Identifying reliable prognostic biomarkers and potential therapeutic targets is crucial for improving patient outcomes.
Methods: We conducted a comprehensive analysis of HJURP expression in LUAD using data from four cohorts: TCGA-LUAD (n = 453), GSE31210 (n = 226), GSE68465 (n = 442), and GSE72094 (n = 386).
IRF4 regulates myeloid-derived suppressor cells expansion and function in Schistosoma japonicum-infected mice.
Parasit Vectors
November 2024
Affiliated Qingyuan Hospital, Qingyuan People's Hospital, Guangzhou Medical University, Qingyuan, 511518, China.
Background: Interferon regulatory factor 4 (IRF4) is a crucial member of the IRF family of transcription factors and is pivotal in orchestrating the body's defense against tumors and infections by modulating the differentiation and functionality of immune cells. The role of IRF4 in mice during Schistosoma japonicum infection, as well as the effects of IRF4 deficiency on myeloid-derived suppressor cells (MDSCs), remains inadequately understood.
Methods: Hematoxylin and eosin staining was used to evaluate the pathological damage in different organs of mice following infection with S.
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.
J Immunother Cancer
November 2024
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Background: Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often harbor PD-L1 and PD-L2 chromosomal amplifications and robust CD8+ T cell infiltrates, and respond at a high rate to anti-PD-1. The current study compares the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(-) GCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!